The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared ...

An add-on agent designed to boost drugs that treat age-related macular degeneration failed to show any benefit in two phase 3 ...

The veteran stockpicker told investors the firm would review how its $220 million wager on the biotech went so wrong “to ...

Shares of UNITY Biotechnology UBX crashed 28.8% yesterday, following mixed results from a mid-stage non-inferiority study of ...

Intravitreal UBX1325 helped patients with diabetic macular edema gain vision but failed to meet its primary analysis endpoint in the ASPIRE clinical trial, according to a press release from Unity ...

Opthea Ltd. is considering its options after lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD). The global Coast phase III trial ...

The entire 36-week data for the remaining subjects in the trial is anticipated in the second quarter of this year.

UBX1325 is a novel BCL-xL inhibitor designed to eliminate senescent cells in diabetic retinal blood vessels, while leaving ...

The phase 3 COAST trial investigating 2 mg sozinibercept for the treatment of wet age-related macular degeneration in ...

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...